-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

Benzinga·07/28/2026 18:21:33
語音播報
UBS analyst Patrick Wood initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Neutral rating and announces Price Target of $19.